52589-11-4
52589-11-4 結(jié)構(gòu)式
基本信息
黃柏甙
二氫黃柏苷
(二氫)黃柏甙
(dihydro) Phellodendron
(2R)-7-(β-D-Glucopyranosyloxy)-2,3-dihydro-3β,5-dihydroxy-2α-(4-hydroxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one
4H-1-Benzopyran-4-one,7-(b-D-glucopyranosyloxy)-2,3-dihydro-3,5-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methyl-2-buten-1-yl)-,(2R,3R)-
4H-1-Benzopyran-4-one, 7-(β-D-glucopyranosyloxy)-2,3-dihydro-3,5-dihydroxy-2-(4-hydroxyphenyl)-8-(3-methyl-2-buten-1-yl)-, (2R,3R)-
物理化學(xué)性質(zhì)
常見問題列表
Phellamurin (0-10?μg/mL; 48 hours; U2OS and Saos-2?cells) treatment leads to a repression of cell viability in U2OS and Saos-2?cells in a dose-dependent manner.
Phellamurin (0-10?μg/mL; 48 hours; U2OS and Saos-2?cells) treatment concentration-dependently promots the apoptosis of U2OS and Saos-2?cells.
Phellamurin (0-10?μg/mL; 48 hours; U2OS and Saos-2?cells) treatment declines the ratios of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR in U2OS and Saos-2?cells.
Cell Viability Assay
| Cell Line: | U2OS and Saos-2?cells |
| Concentration: | 0 μg/mL, 2.5 μg/mL, 5 μg/mL, and 10?μg/mL |
| Incubation Time: | 48 hours |
| Result: | Suppressed the viability of U2OS and Saos-2?cells in a concentration-dependent manner. |
Apoptosis Analysis
| Cell Line: | U2OS and Saos-2?cells |
| Concentration: | 0 μg/mL, 2.5 μg/mL, 5 μg/mL, and 10?μg/mL |
| Incubation Time: | 48 hours |
| Result: | Induced apoptosis of U2OS and Saos-2?cells in a concentration-dependent manner. |
Western Blot Analysis
| Cell Line: | U2OS and Saos-2?cells |
| Concentration: | 0 μg/mL and 10?μg/mL |
| Incubation Time: | 48 hours |
| Result: | Repressed the PI3K/AKT/mTOR pathway in U2OS and Saos-2?cells. |
Phellamurin (50?mg/kg/day; intraperitoneal injection; daily; for 21 days; female BALB/c nude mice) treatment represses osteosarcoma tumor growth in vivo. The ratios of p-PI3K/PI3K, p-AKT/AKT, and p-mTOR/mTOR are decreased in xenograft in Phellamurin-treated mice.
| Animal Model: | Athymic female BALB/c nude mice (6 weeks old ) injected with U2OS cells |
| Dosage: | 50?mg/kg/day |
| Administration: | Intraperitoneal injection; daily; for 21 days |
| Result: | Repressed osteosarcoma tumor growth in vivo. |